BIOA BIOAGE LABS INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIOAGE LABS INC reported revenue of $2.45M (up 1.6% from a year earlier), net income of −$26.1M and diluted EPS of −$0.58; over the last four quarters revenue was $10.4M and net income −$94.5M; for the fiscal year ended December 2025 revenue was $9.00M.
BIOA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $9.00M, gross profit n/a, operating income −$92.8M, net income −$80.6M (margin -896.1%), EPS −$2.24
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$78.2M, net income −$71.1M (margin n/a), EPS −$6.63
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$48.4M, net income −$63.9M (margin n/a), EPS −$38.17
BIOA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $2.45M (up 1.6% year over year), net income −$26.1M, EPS −$0.58
- Quarter ended Mar 31, 2026: revenue $2.77M (up 91.0% year over year), net income −$22.3M, EPS −$0.52
- Quarter ended Dec 31, 2025 (from the annual report): revenue $3.08M, net income −$25.9M, EPS −$0.72
- Quarter ended Sep 30, 2025: revenue $2.05M, net income −$20.2M, EPS −$0.56
- Quarter ended Jun 30, 2025: revenue $2.41M, net income −$21.6M, EPS −$0.60
- Quarter ended Mar 31, 2025: revenue $1.45M, net income −$12.9M, EPS −$0.36
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$21.1M, EPS $15.77
- Quarter ended Sep 30, 2024: revenue $0, net income −$23.4M, EPS −$6.70
- Quarter ended Jun 30, 2024: revenue $0, net income −$13.6M, EPS −$7.94
- Quarter ended Mar 31, 2024: revenue n/a, net income −$13.0M, EPS −$7.76
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$21.0M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$14.6M, EPS −$8.74
- Quarter ended Jun 30, 2023: revenue n/a, net income −$17.2M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$11.1M, EPS n/a
BIOA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$81.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$51.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$37.4M, share buybacks n/a
BIOA balance sheet
- Jun 30, 2026: cash $74.0M, total assets $397M, total liabilities $22.0M, shareholders' equity $375M
- Mar 31, 2026: cash $242M, total assets $398M, total liabilities $18.5M, shareholders' equity $379M
- Dec 31, 2025: cash $189M, total assets $295M, total liabilities $22.8M, shareholders' equity $272M, long-term debt $0
- Sep 30, 2025: cash $216M, total assets $305M, total liabilities $27.6M, shareholders' equity $277M, long-term debt $0
- Jun 30, 2025: cash $220M, total assets $322M, total liabilities $27.4M, shareholders' equity $295M, long-term debt $0
- Mar 31, 2025: cash $257M, total assets $344M, total liabilities $30.7M, shareholders' equity $313M, long-term debt $1.06M
- Dec 31, 2024: cash $354M, total assets $358M, total liabilities $35.1M, shareholders' equity $323M, long-term debt $2.50M
- Sep 30, 2024: cash $334M, total assets $337M, total liabilities $23.6M, shareholders' equity $314M, long-term debt $3.94M
What is BIOA's revenue?
BIOAGE LABS INC reported $10.4M of revenue over its last four quarters, through June 30, 2026.
Is BIOA profitable?
No. BIOAGE LABS INC lost $94.5M over the last four quarters.
What is BIOA's EPS?
Diluted earnings per share over the last four quarters were −$2.38; −$0.58 in the latest quarter.